304 related articles for article (PubMed ID: 32160846)
1. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
Mollica V; Santoni M; Di Nunno V; Cimadamore A; Cheng L; Lopez-Beltran A; Battelli N; Montironi R; Massari F
Curr Drug Targets; 2020; 21(14):1463-1475. PubMed ID: 32160846
[TBL] [Abstract][Full Text] [Related]
2. Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.
Santoni M; Heng DYC; Aurilio G; Iozzelli A; Servi L; Fabiani A; Giannini M; Mazzucchelli R; Cimadamore A; Scarpelli M; Zaghloul MS; Battelli N; Montironi R
Curr Drug Targets; 2020; 21(4):416-423. PubMed ID: 31625471
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature.
Wu M; Liu J; Seery S; Meng X; Yue J
Front Immunol; 2021; 12():646085. PubMed ID: 34211459
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
Deleuze A; Saout J; Dugay F; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Crouzet L; Laguerre B; Belaud-Rotureau MA; Rioux-Leclercq N; Kammerer-Jacquet SF
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260578
[TBL] [Abstract][Full Text] [Related]
6. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
7. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
8. Immune therapy for kidney cancer: a second dawn?
McDermott DF; Atkins MB
Semin Oncol; 2013 Aug; 40(4):492-8. PubMed ID: 23972713
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for renal-cell carcinoma.
De Meerleer G; Khoo V; Escudier B; Joniau S; Bossi A; Ost P; Briganti A; Fonteyne V; Van Vulpen M; Lumen N; Spahn M; Mareel M
Lancet Oncol; 2014 Apr; 15(4):e170-7. PubMed ID: 24694640
[TBL] [Abstract][Full Text] [Related]
11. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
Hah YS; Koo KC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
15. Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report.
Massaccesi M; Boldrini L; Romano A; Rossi E; Schinzari G; Lepre E; Gambacorta MA; Valentini V
Immunotherapy; 2021 Dec; 13(18):1457-1463. PubMed ID: 34664999
[TBL] [Abstract][Full Text] [Related]
16. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy.
Perego G; Barzaghi P; Vavassori I; Petrelli F
Med Oncol; 2020 Aug; 37(9):81. PubMed ID: 32767163
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
[TBL] [Abstract][Full Text] [Related]
18. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences.
Buttigliero C; Allis S; Tucci M; Zichi C; Leone G; Di Stefano RF; Ruo Redda MG; Ricardi U; Scagliotti GV; Di Maio M; Filippi AR
Cancer Treat Rev; 2018 Sep; 69():215-223. PubMed ID: 30096699
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy for Renal Cell Carcinoma].
Büchler T
Klin Onkol; 2015; 28 Suppl 4():4S64-8. PubMed ID: 26647891
[TBL] [Abstract][Full Text] [Related]
20. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma.
Dybal EJ; Haas GP; Maughan RL; Sud S; Pontes JE; Hillman GG
J Urol; 1992 Oct; 148(4):1331-7. PubMed ID: 1404669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
